Short-term changes after a weight reduction intervention in advanced diabetic nephropathy

Clinical Journal of the American Society of Nephrology

Volumn 8, Issue 11, 2013, Pages 1892-1898

  Friedman, Allon N ^a   Chambers, Mary ^a   Kamendulis, Lisa M ^b   Temmerman, Joan ^c  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INDIANA UNIVERSITY   (United States)

^c Fayette Regional Health System   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CREATININE; CYSTATIN C; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLUCOSE; INSULIN; MAGNESIUM; ORAL ANTIDIABETIC AGENT; POTASSIUM; SODIUM; UREA;

ADULT; ARTICLE; CLINICAL TRIAL; DIABETIC NEPHROPATHY; EXERCISE; FEMALE; GLOMERULUS FILTRATION; HUMAN; HYPERINSULINEMIA; INSULIN RESISTANCE; LOW CALORY DIET; MAJOR CLINICAL STUDY; MALE; OBESITY; RISK FACTOR; WEIGHT REDUCTION;

AGED; ALBUMINURIA; BIOLOGICAL MARKERS; BLOOD GLUCOSE; CALORIC RESTRICTION; CREATININE; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; EXERCISE THERAPY; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; HYPOGLYCEMIC AGENTS; INDIANA; INSULIN; INSULIN RESISTANCE; KETOGENIC DIET; KIDNEY; MALE; MIDDLE AGED; OBESITY; PILOT PROJECTS; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 84887050004     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.04010413     Document Type: Article

References (49)

1. de Boer IH, Rue TC, Hall YN, Heagerty PJ, Weiss NS, Himmelfarb J: Temporal trends in the prevalence of diabetic kidney disease in the United States. JAMA 305: 2532-2539, 2011
2. US Renal Data System: USRDS 2012 Annual Data Report: Atlas of End-Stage Renal Disease in the United States, Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2012
3. Wang SL, Head J, Stevens L, Fuller JH: Excess mortality and its relation to hypertension and proteinuria in diabetic patients. The World Health Organization multinational study of vascular disease in diabetes. Diabetes Care 19: 305-312, 1996
4. Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S: Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: The HOPE randomized trial. Ann Intern Med 134: 629-636, 2001
5. Rossing P, de Zeeuw D: Need for better diabetes treatment for improved renal outcome. Kidney Int Suppl (120): S28-S32, 2011
6. Malone M, Alger-Mayer SA, Anderson DA: Medication associated with weight gain may influence outcome in a weight management program. Ann Pharmacother 39: 1204-1208, 2005
7. Slinin Y, Ishani A, Rector T, Fitzgerald P, MacDonald R, Tacklind J, Rutks I, Wilt TJ: Management of hyperglycemia, dyslipidemia, and albuminuria in patientswith diabetes and CKD: A systematic review for a KDOQI clinical practice guideline. Am J Kidney Dis 60: 747-769, 2012
8. Executive summary: Standards of medical care in diabetes-2013. Diabetes Care 36[Suppl 1]: S4-S10, 2013
9. Bray G, Gregg E, Haffner S, Pi-Sunyer XF, WagenKnecht LE, Walkup M, Wing R; Look Ahead Research Group: Baseline characteristics of the randomised cohort from the Look AHEAD (Action for Health in Diabetes) study. Diab Vasc Dis Res 3: 202-215, 2006
10. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM; Diabetes Prevention Program Research Group: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346: 393-403, 2002
11. NationalHeart, Lung, and Blood Institute: ClinicalGuidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults, Bethesda, MD, National Institutes of Health: National Heart, Lung, and Blood Institute, 1998
12. Gugliucci A, Kotani K, Taing J, Matsuoka Y, Sano Y, Yoshimura M, Egawa K, Horikawa C, Kitagawa Y, Kiso Y, Kimura S, Sakane N: Short-termlow calorie diet intervention reduces serum advanced glycation end products in healthy overweight or obese adults. Ann Nutr Metab 54: 197-201, 2009
13. Wycherley TP, Brinkworth GD, Noakes M, Buckley JD, Clifton PM: Effect of caloric restriction with andwithout exercise training on oxidative stress and endothelial function in obese subjects with type 2 diabetes. Diabetes Obes Metab 10: 1062-1073, 2008
14. Seshadri P, Iqbal N, Stern L, Williams M, Chicano KL, Daily DA, McGrory J, Gracely EJ, RaderDJ, Samaha FF: A randomized study comparing the effects of a low-carbohydrate diet and a conventional diet on lipoprotein subfractions and C-reactive protein levels in patients with severe obesity. Am J Med 117: 398-405, 2004
15. Tuck ML, Sowers J, Dornfeld L, Kledzik G, MaxwellM: The effect ofweight reduction on blood pressure, plasma renin activity, and plasma aldosterone levels in obese patients. N Engl J Med 304: 930-933, 1981
16. Foster MC, Hwang SJ, Porter SA, Massaro JM, Hoffmann U, Fox CS: Fatty kidney, hypertension, and chronic kidney disease: The Framingham Heart Study. Hypertension 58: 784-790, 2011
17. Rutkowski JM, Wang ZV, Park AS, Zhang J, ZhangD, Hu MC, Moe OW, Susztak K, Scherer PE: Adiponectin promotes functional recovery after podocyte ablation. J AmSocNephrol 24: 268-282, 2013
18. Sharma K, Ramachandrarao S, Qiu G, Usui HK, Zhu Y, Dunn SR, Ouedraogo R, Hough K, McCue P, Chan L, Falkner B, Goldstein BJ: Adiponectin regulates albuminuria and podocyte function in mice. J Clin Invest 118: 1645-1656, 2008
19. Afshinnia F, Wilt TJ, Duval S, Esmaeili A, Ibrahim HN: Weight loss and proteinuria: Systematic review of clinical trials and comparative cohorts. Nephrol Dial Transplant 25: 1173-1183, 2010
20. Rolland C, Hession M, Murray S, Wise A, Broom I: Randomized clinical trial of standard dietary treatment versus a lowcarbohydrate/ high-protein diet or the LighterLife Programme in the management of obesity. J Diabetes 1: 207-217, 2009
21. Anderson JW, Konz EC, Frederich RC, Wood CL: Long-term weight-loss maintenance: A meta-analysis of US studies. Am J Clin Nutr 74: 579-584, 2001
22. Tsai AG, Wadden TA: The evolution of very-low-calorie diets: An update and meta-analysis. Obesity (Silver Spring) 14: 1283-1293, 2006
23. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412-419, 1985
24. Korchazhkina O, Exley C, Andrew Spencer S: Measurement by reversed-phase high-performance liquid chromatography of malondialdehyde in normal human urine following derivatisation with 2,4-dinitrophenylhydrazine. J Chromatogr B Analyt Technol Biomed Life Sci 794: 353-362, 2003
25. Sim AS, Salonikas C, Naidoo D, Wilcken DE: Improved method for plasma malondialdehyde measurement by high-performance liquid chromatography using methyl malondialdehyde as an internal standard. J Chromatogr B Analyt Technol Biomed Life Sci 785: 337-344, 2003
26. Hays R, Kallich J, Mapes D, Coons D, Amin S, Carter W: Kidney Disease Quality of Life Short Form (KDQOL-SFTM), Version 1.3: A Manual for Use and Scoring, document number P-7994, Santa Monica, CA, RAND Corporation, 1995
27. Koufaki P, Kouidi E: Current best evidence recommendations on measurement and interpretation of physical function in patients with chronic kidney disease. Sports Med 40: 1055-1074, 2010
28. Choudhury D, Tuncel M, Levi M: Diabetic nephropathy-a multifaceted target of new therapies. Discov Med 10: 406-415, 2010
29. Maric-Bilkan C: Obesity and diabetic kidney disease. Med Clin North Am 97: 59-74, 2013
30. Murea M, Freedman BI, Parks JS, Antinozzi PA, Elbein SC, Ma L: Lipotoxicity in diabetic nephropathy: The potential role of fatty acid oxidation. Clin J Am Soc Nephrol 5: 2373-2379, 2010
31. Schena FP, Gesualdo L: Pathogenetic mechanisms of diabetic nephropathy. J Am Soc Nephrol 16[Suppl 1]: S30-S33, 2005
32. Diez-Sampedro A, Lenz O, Fornoni A: Podocytopathy in diabetes: A metabolic and endocrine disorder. Am J Kidney Dis 58: 637-646, 2011
33. Friedman AN, Yu Z, Juliar BE, Nguyen JT, Strother M, Quinney SK, Li L, Inman M, Gomez G, Shihabi Z, Moe S: Independent influence of dietary protein on markers of kidney function and disease in obesity. Kidney Int 78: 693-697, 2010
34. WelshGI, Hale LJ, Eremina V, Jeansson M, Maezawa Y, Lennon R, PonsDA, Owen RJ, Satchell SC, Miles MJ, Caunt CJ, McArdle CA, Pavenstädt H, Tavaré JM, Herzenberg AM, Kahn CR, Mathieson PW, Quaggin SE, Saleem MA, Coward RJ: Insulin signaling to the glomerular podocyte is critical for normal kidney function. Cell Metab 12: 329-340, 2010
35. Weil EJ, Lemley KV, Mason CC, Yee B, Jones LI, Blouch K, Lovato T, Richardson M, Myers BD, Nelson RG: Podocyte detachment and reduced glomerular capillary endothelial fenestration promote kidney disease in type 2 diabetic nephropathy. Kidney Int 82: 1010-1017, 2012
36. Fioretto P, Mauer M: Histopathology of diabetic nephropathy. Semin Nephrol 27: 195-207, 2007
37. Bayliss G, Weinrauch LA, D'Elia JA: Pathophysiology of obesityrelated renal dysfunction contributes to diabetic nephropathy. Curr Diab Rep 12: 440-446, 2012
38. Baxmann AC, Ahmed MS, Marques NC, Menon VB, Pereira AB, Kirsztajn GM, Heilberg IP: Influence of muscle mass and physical activity on serum and urinary creatinine and serum cystatin C. Clin J Am Soc Nephrol 3: 348-354, 2008
39. Tangri N, Stevens LA, Schmid CH, Zhang YL, Beck GJ, Greene T, Coresh J, Levey AS: Changes in dietary protein intake has no effect on serum cystatin C levels independent of the glomerular filtration rate. Kidney Int 79: 471-477, 2011
40. ShlipakMG, SarnakMJ, Katz R, Fried LF, Seliger SL, Newman AB, Siscovick DS, Stehman-Breen C: Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med 352: 2049-2060, 2005
41. Menon V, Shlipak MG, Wang X, Coresh J, Greene T, Stevens L, Kusek JW, Beck GJ, Collins AJ, Levey AS, Sarnak MJ: Cystatin C as a risk factor for outcomes in chronic kidney disease. Ann Intern Med 147: 19-27, 2007
42. Morales E, Valero MA, LeónM, Hernández E, Praga M: Beneficial effects of weight loss in overweight patients with chronic proteinuric nephropathies. Am J Kidney Dis 41: 319-327, 2003
43. Solerte SB, Fioravanti M, Schifino N, Ferrari E: Effects of diettherapy on urinary protein excretion albuminuria and renal haemodynamic function in obese diabetic patients with overt nephropathy. Int J Obes 13: 203-211, 1989
44. Saiki A, Nagayama D, Ohhira M, Endoh K, Ohtsuka M, Koide N, Oyama T, Miyashita Y, Shirai K: Effect of weight loss using formula diet on renal function in obese patients with diabetic nephropathy. Int J Obes (Lond) 29: 1115-1120, 2005
45. Friedman AN, Ogden LG, Foster GD, Klein S, Stein R, Miller B, Hill JO, Brill C, Bailer B, Rosenbaum DR, Wyatt HR: Comparative effects of low-carbohydrate high-protein versus lowfat diets on the kidney. Clin J Am Soc Nephrol 7: 1103-1111, 2012
46. Gumbiner B, Wendel JA, McDermott MP: Effects of diet composition and ketosis on glycemia during very-low-energy-diet therapy in obese patients with non-insulin-dependent diabetes mellitus. Am J Clin Nutr 63: 110-115, 1996
47. Svendsen PF, Jensen FK, Holst JJ, Haugaard SB, Nilas L, Madsbad S: The effect of a very low calorie diet on insulin sensitivity, beta cell function, insulin clearance, incretin hormone secretion, androgen levels and body composition in obese young women. Scand J Clin Lab Invest 72: 410-419, 2012
48. National Task Force on the Prevention and Treatment of Obesity, National Institutes of Health: Very low-calorie diets. JAMA 270: 967-974, 1993
49. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D; Modification of Diet in Renal Disease Study Group: A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Ann Intern Med 130: 461-470, 1999